Growing Demand For At-Home Testing Is Fueling Growth Of The Fecal Calprotectin Test Market


The global fecal calprotectin test market is estimated to be valued at US$ 140.6 Mn in 2023 and is expected to exhibit a CAGR of 12.3% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Fecal calprotectin tests helps in diagnosis of inflammatory bowel disease such as ulcerative colitis and Crohn's disease. The advantages of fecal calprotectin tests are that it is non-invasive, effective and accurate for diagnosing gastrointestinal inflammation and damage.

Market key trends:
One of the key trends in the fecal calprotectin tests market is growing preference for point-of-care and at-home testing. At-home collection and mail-in testing provides convenience to patients. At-home fecal calprotectin tests allow for more frequent non-invasive monitoring of gastrointestinal diseases and their treatments compared to physician office visits. This has supported increased testing volumes and boosted the market growth.

Segment Analysis
The global fecal calprotectin test market is segmented into technology, test type, sample type, end use and region. Based on technology, the market is categorized into enzyme-linked immunosorbent assay (ELISA), calprotectin rapid tests and others. The ELISA segment dominates the market as it is considered the gold standard for detection of fecal calprotectin levels. Based on test type, the market is divided into quantitative and qualitative tests. Quantitative tests hold a larger share as they provide accurate calprotectin level measurement. By sample type, the market covers stool and blood samples, with stool samples being used more widely due to ease of collection. On the basis of end use, the market covers hospitals & clinics, diagnostic laboratories and research & academic institutes. Hospitals & clinics account for the largest share due to high patient footfall.

Key Takeaways
The Global Fecal Calprotectin Test Market Size is expected to witness high growth, exhibiting a CAGR of 12.3% over the forecast period, due to increasing incidence of gastrointestinal disorders.

Regional analysis - North America dominates the global market due to rising prevalence of inflammatory bowel disease. Europe holds the second largest share owing to increasing awareness about fecal calprotectin tests. Asia Pacific exhibits the fastest growth due to growing healthcare infrastructure and healthcare expenditure in countries such as China and India.

Key players - Key players operating in the fecal calprotectin test market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., ALPCO. Thermo Fisher Scientific and F. Hoffmann-La Roche Ltd. hold a major share of the market due to their diversified product portfolios.

Read More: https://www.ukwebwire.com/fecal-calprotectin-test-market-size-share-and-growth-forecast-2023-2023/

Comments

Popular posts from this blog

Contact Center Software Market Growth Accelerated by Enhanced Customer Experience

Microscale 3D Printing Market Growth Accelerated by Advanced Manufacturing Techniques

The Global Seismic Survey Market Growth Accelerated by Increased Oil and Gas E&P Activities